Enitociclib is an experimental CDK9 inhibitor being developed for the treatment of nonHodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). It is currently being tested for safety in phase 1 clinical trials, and thus far, preliminary data show a favorable safety profile.

Dr. Mazyar Shadman from Fred Hutchinson Cancer Center and colleagues presented the results of this trial at the American Society for Hematology (ASH) Annual Meeting in 2022.

Read the full article on CLL Society's website at: https://cllsociety.org/2023/05/enitoc...
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook:   / cllsociety  
Twitter:   / cllsociety  
LinkedIn:   / cllsociety